Taylor Boyd - Oct 1, 2025 Form 4 Insider Report for Avalo Therapeutics, Inc. (AVTX)

Role: Chief Business Officer
Signature: /s/ Donald R. Reynolds, by Power of Attorney
Stock symbol: AVTX
Transactions as of: Oct 1, 2025
Transactions value $: $0
Form type: 4
Date filed: 10/6/2025, 04:28 PM
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Boyd Taylor	Chief Business Officer	C/O AVALO THERAPEUTICS, INC., 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE	/s/ Donald R. Reynolds, by Power of Attorney	2025-10-06	0002090172

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVTX	Stock Option (Right to Buy)	Award	$0	+275K		$0.00	275K	Oct 1, 2025	Common Stock	275K	$12.96	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option was granted on October 1, 2025, and vests over four years, with the first 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to the reporting person's continued employment with the Company on each applicable vesting date.